tiprankstipranks
Vaxcyte’s VAX-31 Shows Promise in Pneumococcal Disease Trial
Company Announcements

Vaxcyte’s VAX-31 Shows Promise in Pneumococcal Disease Trial

Don't Miss our Black Friday Offers:

An update from Vaxcyte (PCVX) is now available.

Vaxcyte, Inc. revealed promising initial results from its study on VAX-31, a vaccine candidate for preventing invasive pneumococcal disease in adults over 50. The Phase 1/2 trial showed that the vaccine was safe, well-tolerated, and effective in generating an immune response, indicating potential for future use in combating this serious infection.

Learn more about PCVX stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyTrump expected to pick Martin Makary to head FDA, Reuters reports
TheFlyVaccine makers fall after Trump nominates RFK to head HHS
TheFlyVaxcyte provides regulatory updates on VAX-31 programs
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App